An observational study in Congenital Heart Disease (CHD) and Congenital Heart Defect, sponsored by HeartWorks, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-25.
Sponsored by HeartWorks, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 356 studies in Heart Defects, Congenital with a site in United States — 67 open to participants now, 87 under way, 4 of them phase 3. Heart Defects, Congenital · United States.
Among the 356 studies in Heart Defects, Congenital with a site in United States, this one is the 69th largest by planned enrollment of the 167 observational ones that give a count, is one of 16 that started in 2024, is one of 170 observational ones, reaches primary completion later than 35 of the 86 other live ones, and was the 328th registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
Browse Heart Defects, Congenital studies →67 of the 356 studies in Heart Defects, Congenital with a site in United States are open now. Recruiting first, the newest first:
University of Nebraska · Sites in United States
Ages 1 mo–3 yrs
Le Bonheur Children's Hospital · Sites in United States
Ages 0 mo–12 mo
Carelon Research · Sites in United States
Ages 18+
Carelon Research · Sites in United States
Ages 18+
The Cleveland Clinic · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
356 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 33 · Phase 3 25 · Phase 4 9
First in 1980; this study’s year is marked. 16 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 119 across 440 observational studies indexed under Heart Defects, Congenital.
Median enrollment 48 across the 184 interventional studies, 72 across the 167 observational. Of the 241 that completed or were terminated, 62 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 356 have an industry lead sponsor. The 10 most frequent:
HeartWorks, Inc. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
HeartWorks, Inc. has 3 studies filed under Heart Defects, Congenital — fewer than ten, so there is no comparison to draw.
29 of the studies in Heart Defects, Congenital with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04216927Phase 3Children's Hospital Medical Center, CincinnatiNO During CPB in Neonates to Reduce Risk of AKI | 2027-06-30 |
| NCT05077774Medtronic CardiovascularHarmony TPV Post-Approval Study | 2026-11 |
| NCT07559253University of Wisconsin, MadisonImplementation of an Accessible Healthcare Model (ACHD STRONG): Comparing Nurse and Physician Lead Healthcare Transition Education in a RE-AIM Framework | 2026-11-30 |
| NCT04236479Catherine BollardMesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP) | 2026-12 |
| NCT05849025Mayo ClinicA Study of Invasive Hemodynamic for MACHD Registry | 2026-12 |
Add all 29 to your calendar (.ics) → With an account.
Among the 356 studies in Heart Defects, Congenital with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a clinical readiness skin punch biopsy sample collection study. This will allow to reduce manufacturing time when patients are identified as eligible to receive product under separate interventional treatment protocol.
This is a clinical readiness skin punch biopsy sample collection study. This will allow to reduce manufacturing time when patients are identified as eligible to receive product under separate interventional treatment protocol.
Congenital heart disease patients likely to qualify in the future for treatment using iPSC-CL in an approved clinical trial under IND 28611
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Successful manufacture of induced pluripotent stem cells
Outcome measured will be the manufacture of iPSC that meets pre-determined acceptance criteria.
Time frame: 12 months
Plan to share: No
Started Sep 2024 (actual). Primary completion is estimated for Jan 2027, 28 months after the start.
Of 178 non-industry observational studies under Heart Defects, Congenital, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 83. This study's planned 28 months is below that.
Counting every sponsor, half of 185 studies reached it within 44 months; a quarter within 17 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
HeartWorks, Inc.